{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:38:58Z","timestamp":1780393138679,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10157-018-1610-2","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T06:32:56Z","timestamp":1532327576000},"page":"112-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic\u2013uremic syndrome in Japan: interim analysis of post-marketing surveillance"],"prefix":"10.1007","volume":"23","author":[{"given":"Shuichi","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,23]]},"reference":[{"issue":"Suppl 11","key":"1610_CR1","first-page":"2","volume":"14","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14(Suppl 11):2\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1610_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","volume":"20","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:536\u201343.","journal-title":"Clin Exp Nephrol"},{"key":"1610_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1610_CR4","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1610_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med"},{"key":"1610_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373.","journal-title":"Kidney Int"},{"key":"1610_CR7","unstructured":"Soliris package insert version 8. In: Soliris website. \n                    http:\/\/www.soliris.jp\/common\/pdf\/Soliris_Tempu_Bunsho_08.pdf\n                    \n                  . Accessed 19 Dec 2017. Japanese."},{"key":"1610_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10157-013-0911-8","volume":"18","author":"T Sawai","year":"2014","unstructured":"Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol. 2014;18:4\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1610_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ped.12274","volume":"56","author":"T Sawai","year":"2014","unstructured":"Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int. 2014;56:1\u20135.","journal-title":"Pediatr Int"},{"key":"1610_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s10157-011-0452-y","volume":"15","author":"O Uemura","year":"2011","unstructured":"Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, et al. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol. 2011;15:694\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1610_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al. Creatinine-based equations to estimate glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626\u201333.","journal-title":"Clin Exp Nephrol"},{"key":"1610_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017; 91:539\u201351.","journal-title":"Kidney Int"},{"key":"1610_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","volume":"32","author":"T Cavero","year":"2017","unstructured":"Cavero T, Rabasco C, L\u00f3pez A, Rom\u00e1n E, \u00c1vila A, Sevillano \u00c1, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32:466\u201374.","journal-title":"Nephrol Dial Transplant"},{"key":"1610_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0195-1","author":"C Licht","year":"2015","unstructured":"Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 2015; \n                    https:\/\/doi.org\/10.1186\/s12882-015-0195-1\n                    \n                  .","journal-title":"BMC Nephrol"},{"key":"1610_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10157-015-1142-y","volume":"20","author":"N Ito","year":"2016","unstructured":"Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:265\u201372.","journal-title":"Clin Exp Nephrol"},{"key":"1610_CR16","doi-asserted-by":"publisher","unstructured":"Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, et al. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017; 18: \n                    https:\/\/doi.org\/10.1186\/s12882-016-0420-6\n                    \n                  .","DOI":"10.1186\/s12882-016-0420-6"},{"key":"1610_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701\u201311.","journal-title":"Kidney Int"},{"key":"1610_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632\u20139.","journal-title":"N Engl J Med"},{"key":"1610_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","volume":"22","author":"S Jodele","year":"2016","unstructured":"Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:307\u201315.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1610_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","volume":"54","author":"S Jodele","year":"2016","unstructured":"Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54:181\u201390.","journal-title":"Transfus Apher Sci"},{"key":"1610_CR21","unstructured":"Request for caution about eculizumab use. In: Japanese Society of Nephrology. \n                    https:\/\/www.jsn.or.jp\/topics\/notice\/_2738.php\n                    \n                  . Accessed 19 Dec 2017. Japanese."},{"key":"1610_CR22","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline. Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D. In: Pharmaceuticals and Medical Devices Agency. \n                    https:\/\/www.pmda.go.jp\/int-activities\/int-harmony\/ich\/0024.html\n                    \n                  . Accessed 19 Dec 2017."},{"key":"1610_CR23","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1111\/ajt.14426","volume":"17","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive Meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of Meningococcal vaccine. Am J Transplant. 2017;17:2481\u20134.","journal-title":"Am J Transplant"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1610-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1610-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1610-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T17:22:15Z","timestamp":1567099335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1610-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1610-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,23]]},"assertion":[{"value":"5 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Employment: Takahisa Matsuda and Akihiko Shimono (Alexion Pharma GK), Advisory role: Yoshitaka Miyakawa (Ablynx, Chugai Pharmaceutical Co., Ltd., FUJIFILM Pharma Co., Ltd, Novartis Pharmaceuticals and Zenyaku Kogyo Co., Ltd.), Stock ownership: Yoshitaka Miyakawa (Preventive Medicine), Patent royalties: Yoshihiro Fujimura (Alfresa Pharma Corporation), Honoraria: Yoshihiko Hidaka, Norimitsu Inoue, Shuichi Ito, Shinya Kaname, Hideki Kato and Masaomi Nangaku (Alexion Pharma GK), Masanori Matsumoto (Alexion Pharma GK and Asahi Kasei Pharma Corporation), Hirokazu Okada (Alexion Pharma GK and Kyowa Hakko Kirin Co. Ltd.), Yoshitaka Miyakawa (Alexion Pharma GK, Bayer Yakuhin, Ltd., Baxalta Japan Limited, Bioverativ, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Kyowa Hakko Kirin Co. Ltd., Novartis Pharmaceuticals, Teijin Pharma Limited and Zenyaku Kogyo Co., Ltd.), Shoichi Maruyama (Alexion Pharma GK, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Kyowa Hakko Kirin Co. Ltd., Mochida Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.), Research funding: Shoichi Maruyama (Sanwa Kagaku Kenkyusho Co., Ltd.) and Masanori Matsumoto (Bayer Yakuhin, Ltd., Baxalta Japan Limited and Chugai Pharmaceutical Co., Ltd.), Subsidies: Masaomi Nangaku (Alexion Pharma GK), Shuichi Ito (Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd. and Pfizer Japan Inc.), Shoichi Maruyama (Alexion Pharma GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Baxter, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co. Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., ROHTO Pharmaceutical Co.,Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited and Torii Pharmaceutical Co.,Ltd) and Hirokazu Okada (Astellas Pharma Inc., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma, MSD K.K., Nippon Boehringer Ingelheim Co., Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited and Torii Pharmaceutical Co.,Ltd.), Endowed departments by commercial entities: Masashi Mizuno (Baxter Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This PMS is conducted in accordance with Good Post-marketing Study Practice for drugs (MHLW Ministerial Ordinance no. 171 of 2004). The requirements of ethical approval by an institutional review board and informed consent from individual patients for this survey were waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}